Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije AJ, Creemers GM, van der Velden A, de Jongh FE, Erdkamp FLG, Tanis BC, Punt CJA, Koopman M. Goey KKH, et al. Ann Oncol. 2017 Sep 1;28(9):2128-2134. doi: 10.1093/annonc/mdx322. Ann Oncol. 2017. PMID: 28911067 Free article. Clinical Trial.
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M. Goey KKH, et al. Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9. Br J Cancer. 2017. PMID: 29123255 Free PMC article. Clinical Trial.
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. van Rooijen KL, et al. Among authors: goey kkh. Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30. Eur J Cancer. 2018. PMID: 29353165
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Goey KKH, et al. Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22. Eur J Cancer. 2018. PMID: 29936065
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
Adams R, Goey K, Chibaudel B, Koopman M, Punt C, Arnold D, Hinke A, Hegewisch-Becker S, de Gramont A, Labianca R, Diaz Rubio E, Magne Tveit K, Wasan H, Kaplan R, Brown L, Maughan T, Fisher D. Adams R, et al. Cancer Treat Rev. 2021 Sep;99:102226. doi: 10.1016/j.ctrv.2021.102226. Epub 2021 May 19. Cancer Treat Rev. 2021. PMID: 34130171 Review.
Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.
Ten Hoorn S, Waasdorp C, van Oijen MGH, Damhofer H, Trinh A, Zhao L, Smits LJH, Bootsma S, van Pelt GW, Mesker WE, Mol L, Goey KKH, Koopman M, Medema JP, Tuynman JB, Zlobec I, Punt CJA, Vermeulen L, Bijlsma MF. Ten Hoorn S, et al. Among authors: goey kkh. BMC Cancer. 2022 Apr 12;22(1):394. doi: 10.1186/s12885-022-09436-0. BMC Cancer. 2022. PMID: 35413826 Free PMC article.